

1 **Reduced seroconversion in children compared to adults with mild COVID-19**

2 \*Zheng Quan Toh (PhD)<sup>1,2</sup>, \*Jeremy Anderson (BSc Hons)<sup>1,2</sup>, Nadia Mazarakis (MBe)<sup>1</sup>,  
3 Melanie Neeland (PhD)<sup>1,2</sup>, Rachel A. Higgins (BBiomed Hons)<sup>1</sup>, Karin Rautenbacher  
4 (BAppSc)<sup>3</sup>, Kate Dohle (BSc Hons)<sup>1</sup>, Jill Nguyen (BSc Hons)<sup>1</sup>, Isabella Overmars (MPH)<sup>1</sup>,  
5 Celeste Donato (PhD)<sup>1,2</sup>, Sohinee Sarkar (PhD)<sup>1,2</sup>, Vanessa Clifford<sup>7</sup> (PhD), Andrew Daley  
6 (PhD)<sup>7</sup>, Suellen Nicholson (BSc)<sup>4</sup>, Francesca L. Mordant (MSc)<sup>5,6</sup>, Kanta Subbarao  
7 (M.B.B.S.)<sup>5,6</sup>, David P. Burgner<sup>1,2,7</sup>, Nigel Curtis (MD)<sup>1,2,7</sup>, Julie E. Bines (MD)<sup>1,2,8</sup>, Sarah  
8 McNab (MD)<sup>1,7</sup>, Andrew C. Steer (PhD)<sup>1,2,7</sup>, Kim Mulholland (MD)<sup>1,2,9</sup>, Shidan Tosif  
9 (PhD)<sup>1,2,7</sup>, Nigel W. Crawford (MD)<sup>1,2,7</sup>, Daniel G. Pellicci (PhD)<sup>1</sup>, ^Lien Anh Ha Do (PhD)<sup>1,2</sup>  
10 and ^Paul V Licciardi (PhD)<sup>1,2</sup>

11

12 <sup>1</sup>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Australia

13 <sup>2</sup>Department of Paediatrics, The University of Melbourne, Melbourne, Australia

14 <sup>3</sup>Laboratory Services, The Royal Children's Hospital, Melbourne, Australia

15 <sup>4</sup>Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter  
16 Doherty Institute for Infection and Immunity, Melbourne, Australia

17 <sup>5</sup>The University of Melbourne, Peter Doherty Institute for Infection and Immunity,  
18 Melbourne, Australia

19 <sup>6</sup>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute  
20 for Infection and Immunity, Melbourne, Australia

21 <sup>7</sup>Department of General Medicine, The Royal Children's Hospital, Melbourne, Australia

22 <sup>8</sup>Department of Gastroenterology, The Royal Children's Hospital, Melbourne, Australia

23 <sup>9</sup>Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical  
24 Medicine, London, UK

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 \*co-first author

27 ^co-last author

28

29 Word count: 3075

30

31 Author for correspondence:

32 Paul V Licciardi

33 Murdoch Children's Research Institute

34 Royal Children's Hospital

35 Flemington Road, Parkville, Victoria 3052 Australia

36 Email: [paul.licciardi@mcri.edu.au](mailto:paul.licciardi@mcri.edu.au)

37 **Key points**

38 **Question:** What proportion of children with non-hospitalized (mild) SARS-CoV-2 infection  
39 seroconvert compared to adults?

40

41 **Findings:** In this cohort study conducted in 2020, we found the proportion of children who  
42 seroconverted to SARS-CoV-2 was half that in adults despite similar viral load.

43

44 **Meaning:** Serology is a less reliable marker of prior SARS-CoV-2 infection in children. SARS-  
45 CoV-2-infected children who do not seroconvert may be susceptible to reinfection. Our  
46 findings support strategies to protect children against COVID-19 including vaccination.

47

48 **Abstract**

49 **Importance:** The immune response in children with SARS-CoV-2 infection is not well  
50 understood.

51

52 **Objective:** To compare seroconversion in children and adults with non-hospitalized (mild)  
53 SARS-CoV-2 infection and to understand the factors that influence this.

54

55 **Design:** Participants were part of a household cohort study of SARS-CoV-2 infection. Weekly  
56 nasopharyngeal/throat swabs and blood samples were collected during the acute and  
57 convalescent period following PCR diagnosis for analysis.

58

59 **Setting:** Participants were recruited at the Royal Children's Hospital, Melbourne, Australia  
60 between May and October 2020.

61

62 **Participants:** Those who had a SARS-CoV-2 PCR-positive nasal/throat swab.

63

64 **Main outcomes and measures:** SARS-CoV-2 antibody and cellular responses in children and  
65 adults. Seroconversion was defined by seropositivity in all three serological assays.

66

67 **Results:** Among 108 SARS-CoV-2 PCR-positive participants, 57 were children (median age:  
68 4, IQR 2-10) and 51 were adults (median age: 37, IQR 34-45). Using three established  
69 serological assays, a lower proportion of children seroconverted compared with adults [20/54  
70 (37.0%) vs 32/42 (76.2%); ( $p < 0.001$ )]. This was not related to viral load, which was similar in  
71 children and adults [mean Ct 28.58 (SD: 6.83) vs 24.14 (SD: 8.47)]. Age and sex also did not  
72 influence seroconversion or the magnitude of antibody response within children or adults.  
73 Notably, in adults (but not children) symptomatic adults had three-fold higher antibody levels  
74 than asymptomatic adults (median 227.5 IU/mL, IQR 133.7-521.6 vs median 75.3 IU/mL, IQR  
75 36.9-113.6). Evidence of cellular immunity was observed in adults who seroconverted but not  
76 in children who seroconverted.

77

78 **Conclusion and Relevance:** In this non-hospitalized cohort with mild COVID-19, children  
79 were less likely to seroconvert than adults despite similar viral loads. This has implications for  
80 future protection following COVID-19 infection in children and for interpretation of  
81 serosurveys that involve children. Further research to understand why children are less likely  
82 to seroconvert and develop symptoms following SARS-CoV-2 infection, and comparison with  
83 vaccine responses may be of clinical and scientific importance.

84

85

## 86 **Introduction**

87           Since the start of the COVID-19 pandemic, most children with COVID-19 have been  
88 either asymptomatic or present with mild illness, and very few require hospitalization<sup>1-3</sup>.  
89 However, COVID-19 cases in children are increasing in 2021 due to the emergent of SARS-  
90 CoV-2 variants, particularly the Delta variant, posing important questions regarding the  
91 immune responses in children<sup>4,5</sup>. While the severity of COVID-19 generally correlates with the  
92 magnitude of host immune responses against SARS-CoV-2<sup>6,7</sup>, children and adolescents with  
93 mild or asymptomatic SARS-CoV-2 infection can also mount robust and durable antibody  
94 responses<sup>8</sup>.

95           Immunity to SARS-CoV-2 induced through natural infection is likely to be mediated  
96 by a combination of humoral and cellular immunity<sup>9-11</sup>. Some studies comparing children and  
97 adults have revealed distinct immune profiles<sup>12-15</sup>, which have been associated with less severe  
98 outcomes in children compared with adults.

99           The correlates of protection against SARS-CoV-2 have not been identified, although  
100 neutralizing antibodies are increasingly recognized as the primary mediator of protection<sup>16-18</sup>.  
101 The majority of adults (>90%) infected with SARS-CoV-2 mount an antibody response<sup>19,20</sup>,  
102 which can persist for at least 12 months<sup>21</sup>. Seropositive recovered adults are estimated to have  
103 up to 89% protection from reinfection against the same strain<sup>22,23</sup>. In contrast, the proportion  
104 of children infected with SARS-CoV-2 who seroconvert is unknown, particularly among those  
105 with asymptomatic or mild infection.

106           Characterization of the immune response following natural infection is important to  
107 better understand factors that may be related to future protection. In this study, we compared  
108 seroconversion and cellular immunity in children and adults following infection with the  
109 ancestral (Wuhan) strain of SARS-CoV-2 and investigated the factors associated with this  
110 response in a household cohort study in Melbourne, Australia.

## 111 **Methods**

### 112 *Study cohort*

113 Participants were recruited as part of a household cohort study at The Royal Children's  
114 Hospital, Melbourne, Australia between May and October 2020. Infection with SARS-CoV-2  
115 was confirmed by PCR of nasopharyngeal/oropharyngeal (NP) swabs. Participants were non-  
116 hospitalized patients who were asymptomatic or had mild symptoms of COVID-19 (i.e. coryza,  
117 headaches, nausea, fever, cough, sore throat, malaise and/or muscle aches). Baseline swab and  
118 convalescent blood samples (median 41 days, interquartile range, IQR: 31-49) were collected  
119 from all individuals. A subset of individuals had two to four additional weekly NP swabs and  
120 a baseline blood sample collected (median 7-12 days, IQR: 4-13 following the baseline swab),  
121 as well as a later blood sample collected at median 94 days (IQR: 91-100). Written informed  
122 consent and assent were obtained from adults/parents and children, respectively. The study was  
123 done with the approval of the Human Research Ethics Committee (HREC) at the Royal  
124 Children's Hospital, Melbourne: HREC/63666/RCHM-2019.

125

### 126 *SARS-CoV-2 PCR diagnosis*

127 Combined oropharyngeal and nasopharyngeal (or deep nasal) swabs were collected  
128 using dry FLOQSwabs® (Copan, Brescia, Italy). Briefly, FLOQSwabs were eluted in  
129 phosphate buffered saline (PBS) and the eluent was used for nucleic acid extraction using the  
130 Roche MagNA Pure 96 extraction system (Roche, Basel, Switzerland), according to the  
131 manufacturer's instructions. The majority of SARS-CoV-2 samples were initially tested using  
132 the LightMix® Modular SARS and Wuhan CoV E-gene kit (targeting the E-gene; sensitivity  
133 96.5%, specificity of 98.5%<sup>24</sup>; TIB Molbiol, Berlin, Germany) using 10 µL nucleic acid  
134 extract, according to the manufacturer's instructions. RT-qPCR was performed on the

135 LightCycler 480 II Real-Time PCR System (Roche). Ct values at diagnosis for SARS-CoV-2  
136 positive patients are provided, when available.

137

138 *SARS-CoV-2 serology diagnosis*

139 - *In-house ELISA method*

140 We used a modified two-step ELISA based on the Mount Sinai Laboratory method  
141 previously described <sup>25,26</sup>. Briefly, 96-well high-binding plates were coated with receptor  
142 binding domain (RBD) or S1 (Sino Biological, China) antigen diluted in PBS at 2 µg/mL.  
143 Serum samples were first screened with RBD antigen, and potential seropositive samples were  
144 then confirmed with S1 antigen. Goat anti-human IgG- (1:10,000) horseradish peroxidase  
145 (HRP) conjugated secondary antibody was used, and the plates were developed using 3.3',  
146 5.5'-tetramethylbenzidine substrate solution. Seropositive samples were titrated and calculated  
147 based on a World Health Organization (WHO) SARS-CoV-2 pooled serum standard (National  
148 Institute of Biological Standards and Controls, United Kingdom). Results were reported in  
149 International Units/mL. The cut-off for seropositivity was 8.36 IU/mL based on pre-pandemic  
150 samples, while seronegative samples were given half of the seropositive cut-off value.

151

152 - *Liaison SARS-CoV-2 S1/S2 IgG assay (Saluggia, Italy)*

153 The quantitative commercial assay for the detection of IgG antibodies against S1/S2  
154 antigens of SARS-CoV-2 was done according to the manufacturer's instructions. Data was  
155 reported as Assay Units (AU)/mL; negative (<12.0 AU/mL), equivocal (12.0-15.0 AU/mL), or  
156 positive (>15.0 AU/mL).

157

158 - *Wantai SARS-CoV-2 antibody ELISA (Beijing, China)*

159 This qualitative commercial assay detects total antibodies (including IgG and IgM) to  
160 SARS-CoV-2 RBD antigen. The assays were done according to the manufacturer's

161 instructions. Data was reported as a ratio of the absorbance over the kit control cut-off;  
162 seropositive is defined as ratio  $\geq 1.0$ .

163

#### 164 *Flow cytometry*

165 For T- and B- cell populations (convalescent sample), whole blood was lysed with red  
166 blood cell lysis buffer (1:10 dilution) for 10 min at room temperature (RT). Whole blood was  
167 then diluted in PBS and centrifuged at 400 x g for 5 min. Cells were washed once more in PBS  
168 then resuspended in 50  $\mu$ L blocking solution (1% FC-block and 5% normal rat serum in PBS)  
169 for 15 min on ice. Following blocking, cells were washed with 1 mL of FACS buffer (2% FBS  
170 in PBS) then stained with 50  $\mu$ L of antibody cocktail 1 or 2 for 20 min on ice (Supplementary  
171 Table 1). After staining, cells were washed twice then resuspended in 100  $\mu$ L of FACS buffer  
172 for acquisition using the Cytex Aurora. Compensation was performed at the time of acquisition  
173 using compensation beads (BD Bioscience, San Diego, CA, USA). Data were analysed by  
174 FlowJo (Tree Star). Supplementary Figures 1 and 2 depicts the manual gating strategy for B-  
175 and T cell panels.

176 For innate cell populations (baseline sample), 100  $\mu$ L of whole blood was aliquoted for  
177 flow cytometry analysis. Whole blood was lysed with 1 mL of red cell lysis buffer for 10 min  
178 at room temperature. Cells were washed with 1mL PBS and centrifuged at 350 x g for 5 min.  
179 Following two more washes, cells were resuspended in PBS for viability staining using near  
180 infra-red viability dye according to manufacturer's instructions. The viability dye reaction was  
181 stopped by the addition of FACS buffer (2% heat-inactivated FCS in 2 mM EDTA) and cells  
182 were centrifuged at 350 x g for 5 min. Cells were then resuspended in human FC-block for 5  
183 min at room temperature. The whole blood innate cocktail (Supplementary Table 2) made up  
184 at 2X concentration were added 1:1 with the cells and incubated for 30 min on ice. Following  
185 staining, cells were washed with 2 mL FACS buffer and centrifuged at 350 x g for 5 min. Cells



186 were then resuspended in 2% PFA for a 20 min fixation on ice, washed, and resuspended in  
187 150 $\mu$ L FACS buffer for acquisition using the BD LSR X-20 Fortessa. Supplementary Figure 3  
188 depicts the manual gating strategy for innate cell populations.

189

### 190 *Statistical analysis*

191 The antibody levels and Ct values between children and adults, as well as within  
192 seropositive/seronegative children or adults were compared using Mann-Whitney U test.  
193 Fisher's exact test was used to compare both the proportion who were seropositive and the  
194 proportion who were symptomatic in children and adults. For correlation analysis, antibody  
195 levels were log-transformed and analyzed using Pearson's correlation analysis. All analyses  
196 were performed with GraphPad Prism 7.0. A  $p < 0.05$  was considered significant.

197

## 198 **Results**

### 199 *Participants' characteristics*

200 Between May 10, 2020 and October 28, 2020, 134 children (less than 18 years of age)  
201 and 160 adults (19–73 years of age) from 95 families were recruited into the household cohort  
202 study. A total of 57/134 children (42.5%) and 51/160 adults (31.9%) were infected with SARS-  
203 CoV-2 (defined as having a positive PCR result for SARS-CoV-2 at any of the five timepoints)  
204 and were included in our analysis; 30/57 children and 19/51 adults had two to four additional  
205 weekly swabs collected. Four adults were PCR negative at baseline but returned a positive PCR  
206 result one week later. The median ages at enrolment for children was 4 years old (IQR: 2-10)  
207 and 37 years old for adults (IQR: 34-45). Among them, 22/57 (38.6%) children and 28/51  
208 (54.9%) were female.

209

210 *Fewer children seroconvert compared to adults*

211 Two commercial and one in-house assay were used to measure antibody responses in  
212 children and adults at acute (median day 7-12, IQR: 4-13) and convalescence timepoints  
213 (median day 41, IQR: 31-49). There was a significant increase in antibody levels between acute  
214 and convalescence for adults but not in children for all three assays (Fig. 1A). Results from all  
215 three assays were highly concordant, with 96/108 (88.9%) samples positive by all three assays  
216 (Fig. 1B, Supplementary Fig. 4), and 94-97% agreement between the assays (Supplementary  
217 Table 3). A subset of these samples was also tested by a SARS-CoV-2 microneutralization  
218 assay and the results positively correlated with results from all three assays (Supplementary  
219 Fig. 5). Interestingly, lower seropositivity was found in SARS-CoV-2-infected children (40.4-  
220 40.7%) at the convalescent timepoint compared to adults (61.4-73.7%, depending on the assay)  
221 (Fig. 1C). All seronegative children at the median convalescent timepoint (Day 41) did not  
222 become seropositive by the median Day 94 timepoint. (Fig. 1D).

223

224 *Factors that may influence the antibody response*

225 To investigate the factors involved in seroconversion, we included only those  
226 participants who were seropositive or seronegative by all three serological assays (Fig. 2A); 9  
227 samples from adults and 3 from children were excluded due to inconsistent serostatus or not  
228 tested on all assays due to sample availability. We found no difference in viral loads at baseline  
229 between children and adults [mean Ct 28.58 (SD: 6.83) vs mean Ct 24.14 (SD: 8.47)] (Fig.  
230 2B). The time between PCR diagnosis to convalescent sampling was also similar (median days  
231 41, IQR, 31-49 vs median days 41, IQR, 35-49) (Fig 2C).

232 Individuals were more likely to be seropositive with higher viral loads and longer viral  
233 clearance time (based on those with multiple swabs collected), but there were no differences in  
234 these parameters between children and adults who were seronegative or seropositive (Fig 2D-

235 E). Interestingly, a Ct value of less than 26 was associated with seroconversion in 80% (12/15)  
236 and 91% (10/11) children and adults, respectively. The proportion of children and adults who  
237 were seropositive were similar when stratified by sex (Fig. 2F). A similar age was observed  
238 between seronegative and seropositive children as well as between seronegative and  
239 seropositive adults (Fig 2G).

240 When examining the relationship between symptomatic infection and antibody  
241 response, a higher proportion of seronegative adults were asymptomatic compared to  
242 seropositive adults (4/10, 40% vs. 2/32, 6.3%;  $p=0.02$ ) (Fig. 2H). Symptomatic adults on  
243 average had three times more antibodies than asymptomatic adults (median 227.5 IU/mL, IQR  
244 133.7-521.6 vs. median 75.3 IU/mL, IQR 36.9-113.6) and higher viral load (not statistically  
245 significant) than asymptomatic adults, although the number of adults who were asymptomatic  
246 and seropositive was small (Fig. 2I-J). In contrast, a higher proportion of seropositive children  
247 were asymptomatic compared to seronegative children (although not statistically significant)  
248 (Fig. 2H), and similar levels of antibodies and viral load were observed in children regardless  
249 of whether they had any symptoms (Fig 2I-J). Notably, viral load correlated with antibody  
250 levels (Fig. 2K) but not age (Fig. 2L) in both children and adults.

251

### 252 *Cellular immune response in children and adults following SARS-CoV-2 infection*

253 At the convalescent timepoint, seropositive adults had a significantly lower frequency  
254 of IgG+ memory B cells, with a corresponding increase in transitional B cells, CD4+ and CD8+  
255 T effector memory ( $T_{EM}$ ) cells compared with uninfected adults. These differences were also  
256 observed between seropositive and seronegative adults but were not statistically significant  
257 (Fig. 3). There were no differences in IgG+ memory B cells, CD4+  $T_{EM}$  or CD8+  $T_{EM}$  cells in  
258 children, however seropositive and seronegative children showed higher levels of transitional  
259 B cells compared with uninfected children (Fig. 3). No other differences were observed for any

260 of the other cell populations examined in children or adults (Supplementary Fig. 6). We also  
261 compared innate responses during the acute phase in children and adults. We found no  
262 differences in innate immune responses for both children and adults based on serostatus,  
263 although the number of samples available for this analysis was small (Supplementary Fig. 7).

264

## 265 **Discussion**

266 Our study found that a lower proportion of children with confirmed SARS-CoV-2  
267 infection seroconverted compared with adults despite no difference in viral load. However,  
268 SARS-CoV-2 infection in adults generated changes in cellular immune profiles that were most  
269 evident in seropositive adults, while this was not observed in children except for transitional B  
270 cells. Taken together, our findings provide insights into how children and adults respond  
271 differently to the virus. Reduced likelihood of seroconversion may mean that children are less  
272 protected against SARS-CoV-2 infections in the long term compared to adults.

273 Several factors such as age, viral load, sex, comorbidities (including diabetes, cancer  
274 and immunosuppression) and disease severity have been found to influence SARS-CoV-2  
275 antibody responses<sup>27-35</sup>. To the best of our knowledge, no data on the proportion of SARS-  
276 CoV-2 infected children who seroconvert and the factors impacting this have been reported. A  
277 recent study found that 36% of adults with mild COVID-19 did not seroconvert<sup>36</sup>. In  
278 comparison to adults who seroconverted, seronegative adults had lower viral load in their  
279 respiratory tract and were younger (50 vs 40 years)<sup>36</sup>. The proportion of adults who did not  
280 seroconvert were similar to that observed in our study. Other studies in adults have reported  
281 variable seroconversion rates between 5 and 25%<sup>30,37-39</sup>. Viral load was similar between  
282 children and adults in our cohort, which does not explain why fewer children seroconverted  
283 compared with adults. However, our data suggests that Ct value of less than 26 is associated  
284 with seroconversion in both children and adults. A similar Ct value threshold of 25 was found

285 to be associated with seroconversion in a previous study<sup>40</sup>. Interestingly, asymptomatic  
286 infection was associated with lower seropositivity and antibody levels in adults but not in  
287 children, consistent with previous studies in adults<sup>35,41</sup> and children<sup>8</sup>. This suggests that the host  
288 humoral response to SARS-CoV-2 infection in children is different to adults despite similar  
289 viral loads and circulating virus variant exposure.

290         There are several immunological hypotheses as to why children might be less likely to  
291 seroconvert. First, antibody profiles (antibody isotypes and subclasses)<sup>12,14,42-44</sup> and memory B  
292 cell populations have been reported to be different between children and adults, but this has  
293 mostly been related to disease severity<sup>45,46</sup>. We<sup>25</sup> and others<sup>12,20,42,43,47</sup> have previously reported  
294 similar SARS-CoV-2 specific IgG antibody levels between children and adults. We however  
295 did not measure IgG subclasses (i.e. IgG1 and IgG3) which have also been associated with  
296 COVID-19 severity as well as age effects<sup>14,44</sup>. In our study, we observed a decrease in IgG  
297 memory B cells among seropositive adults that corresponded with an increase in transitional B  
298 cells in SARS-CoV-2-infected children and adults. One explanation for this is that activation  
299 of pre-existing memory B cells during SARS-CoV-2 infection leads to increased transitional  
300 B cells to compensate for the loss in the B cell compartment<sup>48,49</sup>. Whether transitional B cells  
301 play a role in seroconversion remains to be determined.

302         Second, T cell responses differ between SARS-CoV-2 infected children and adults. A  
303 recent study of SARS-CoV-2 T cell responses in children and adults with mild COVID-19  
304 found that infected children had reduced CD4+ T cell effector memory to SARS-CoV-2  
305 proteins compared to infected adults<sup>50</sup>, consistent with our findings although we did not  
306 undertake *ex vivo* stimulation experiments. Our data supports the concept that infection may  
307 not induce the robust cellular immune responses in children that are necessary for  
308 seroconversion as seen in adults<sup>51,52</sup>.

309 Children are thought to have a more robust innate and/or mucosal immune response to  
310 SARS-CoV-2 than adults<sup>13,15,53-55</sup>. This could explain why children in our study did not appear  
311 to trigger the adaptive immune system as well as adults. However, our analysis of innate  
312 immune responses in children by serostatus did not reveal any differences, likely due to the  
313 small sample size. More efficient innate immunity may also suggest a shorter viral clearance  
314 time in seronegative children, but this was not observed in our study. We previously showed  
315 that the appearance of mucosal SARS-CoV-2 antibody levels in children was associated with  
316 symptom resolution and lack of seroconversion in a family case study<sup>53</sup>. Further analysis of  
317 mucosal responses in children are ongoing. Clearly, several factors are likely to contribute to  
318 the lack of seroconversion, and more studies are needed to improve our understanding of this  
319 response.

320 Our findings have important implications for protection against SARS-CoV-2 in  
321 children. Numerous studies have highlighted the importance of antibodies for protection  
322 against SARS-CoV-2. A US study of SARS-CoV-2-infected young adults (18-20 years)  
323 reported that SARS-CoV-2-infected seronegative individuals were 80% more likely to be  
324 reinfected compared to seropositive individuals. The study also found that low IgG antibody  
325 levels in seropositive individuals were associated with reinfection, although seropositive adults  
326 had 10-times lower viral load than reinfected seronegative individuals<sup>56</sup>. Therefore, a lack of  
327 seroconversion may result in a higher susceptibility to reinfection. This may have important  
328 implications on the transmission of SARS-CoV-2 in the community and the public health  
329 response.

330 It is important to note that our findings are based on the ancestral ‘Wuhan’ SAR-CoV-  
331 2 virus that was circulating in 2020. The relevance of our findings to current epidemiology  
332 where COVID-19 cases in children have been rising due to the SARS-CoV-2 Delta variant<sup>57</sup>  
333 is unclear. Whether lower seroconversion rates in children are also observed following

334 infection with Delta variant is unknown and warrants further research. This variant has been  
335 associated with 1000x higher viral load compared with the Wuhan strain so a higher  
336 seroconversion rate in children might be expected<sup>58</sup>.

337 The strengths of our study includes the use of three independent serological assays to  
338 examine antibody response against SARS-CoV-2, including a subset of samples that correlated  
339 positively with neutralizing antibody assay; these assays have also previously been shown to  
340 correlate well with neutralizing antibody assays<sup>25,59,60</sup>. Limitations of this study include the  
341 small sample size particularly for the cellular analyses. In addition, our study cohort of mild  
342 COVID-19 among children and adults may not be generalizable to other study populations  
343 such as older adults or individuals with underlying medical conditions.

344 This is the first study that documents a higher proportion of children who do not  
345 seroconvert compared to adults, despite a similar clinical and virological profile. Seronegative  
346 children are at a greater potential risk of reinfection. Our findings have important implications  
347 for public health responses in controlling SARS-CoV-2 infection among children and supports  
348 COVID-19 vaccination strategies once priority groups have been vaccinated.

349

### 350 *Acknowledgments*

351 We thank the study participants and families for their involvement in this study. We also  
352 acknowledge the MCRI Biobanking service for their help in processing the samples. Funding  
353 for the recruitment of participants was provided by the Royal Children's Hospital Foundation  
354 and the Infection and Immunity Theme, MCRI. PVL is supported by NHMRC Career  
355 Development Fellowship. D.G.P is supported by a CSL centenary fellowship. K.S. is supported  
356 by a National Health and Medical Research Council Investigator grant; her research is  
357 supported by funding from the Jack Ma Foundation and the A2 Milk Company. This work is  
358 supported by Victorian Government's Medical Research Operational Infrastructure Support

359 Program. NWC and KS received funding from the National Institute of Health for influenza  
360 and COVID-19 research. All other authors reported no conflicts of interests.  
361



## 362 References


- 363 1. Dawood FS, Ricks P, Njie GJ, et al. Observations of the global epidemiology of COVID-19 from  
364 the prepandemic period using web-based surveillance: a cross-sectional analysis. *Lancet*  
365 *Infect Dis.* 2020;20(11):1255-1262.
- 366 2. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An  
367 Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention  
368 Options in Children. *Pediatr Infect Dis J.* 2020;39(5):355-368.
- 369 3. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed  
370 mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. *Arch*  
371 *Dis Child.* 2020.
- 372 4. BMJ. Covid-19: Cases in children rise sharply in US as doctors call for vaccine approval. *BMJ.*  
373 2021(374).
- 374 5. Munoz FM. If Young Children's Risk of SARS-CoV-2 Infection Is Similar to That of Adults, Can  
375 Children Also Contribute to Household Transmission? *JAMA Pediatr.* 2021.
- 376 6. Lucas C, Klein J, Sundaram ME, et al. Delayed production of neutralizing antibodies  
377 correlates with fatal COVID-19. *Nat Med.* 2021;27(7):1178-1186.
- 378 7. Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing  
379 antibody responses in COVID-19. *Signal Transduct Target Ther.* 2020;5(1):180.
- 380 8. Garrido C, Hurst JH, Lorang CG, et al. Asymptomatic or mild symptomatic SARS-CoV-2  
381 infection elicits durable neutralizing antibody responses in children and adolescents. *JCI*  
382 *Insight.* 2021.
- 383 9. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of  
384 COVID-19 and SARS, and uninfected controls. *Nature.* 2020;584(7821):457-462.
- 385 10. Castro Dopico X, Ols S, Lore K, Karlsson Hedestam GB. Immunity to SARS-CoV-2 induced by  
386 infection or vaccination. *J Intern Med.* 2021.
- 387 11. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T  
388 cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. *J Clin Invest.*  
389 2021;131(10).
- 390 12. Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children  
391 and adults across the COVID-19 clinical spectrum. *Nat Immunol.* 2021;22(1):25-31.
- 392 13. Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in  
393 hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12(564).
- 394 14. Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally distinct  
395 coronavirus antibody features in children and elderly. *Nat Commun.* 2021;12(1):2037.
- 396 15. Neeland MR, Bannister S, Clifford V, et al. Innate cell profiles during the acute and  
397 convalescent phase of SARS-CoV-2 infection in children. *Nat Commun.* 2021;12(1):1084.
- 398 16. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med.*  
399 2021;27(7):1147-1148.
- 400 17. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of  
401 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27(7):1205-  
402 1211.
- 403 18. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective  
404 correlate for COVID-19 vaccines. *Vaccine.* 2021;39(32):4423-4428.
- 405 19. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2  
406 in Iceland. *N Engl J Med.* 2020;383(18):1724-1734.
- 407 20. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection  
408 persist for months. *Science.* 2020;370(6521):1227-1230.
- 409 21. Feng C, Shi J, Fan Q, et al. Protective humoral and cellular immune responses to SARS-CoV-2  
410 persist up to 1 year after recovery. *Nat Commun.* 2021;12(1):4984.

- 411 22. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2  
412 Infection in Health Care Workers. *N Engl J Med.* 2021;384(6):533-540.
- 413 23. Rovida F, Cassaniti I, Percivalle E, et al. Incidence of SARS-CoV-2 infection in health care  
414 workers from Northern Italy based on antibody status: immune protection from secondary  
415 infection- A retrospective observational case-controlled study. *Int J Infect Dis.* 2021;109:199-  
416 202.
- 417 24. Procop GW, Brock JE, Reineks EZ, et al. A Comparison of Five SARS-CoV-2 Molecular Assays  
418 With Clinical Correlations. *American journal of clinical pathology.* 2020.
- 419 25. Toh ZQ, Higgins RA, Do LAH, et al. Persistence of SARS-CoV-2-Specific IgG in Children 6  
420 Months After Infection, Australia. *Emerg Infect Dis.* 2021;27(8):2233-2235.
- 421 26. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2  
422 seroconversion in humans. *Nat Med.* 2020;26(7):1033-1036.
- 423 27. Yang HS, Costa V, Racine-Brzostek SE, et al. Association of Age With SARS-CoV-2 Antibody  
424 Response. *JAMA Netw Open.* 2021;4(3):e214302.
- 425 28. Waterfield T, Watson C, Moore R, et al. Seroprevalence of SARS-CoV-2 antibodies in  
426 children: a prospective multicentre cohort study. *Arch Dis Child.* 2020.
- 427 29. Yazaki S, Yoshida T, Kojima Y, et al. Difference in SARS-CoV-2 Antibody Status Between  
428 Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.  
429 *JAMA Oncol.* 2021;7(8):1141-1148.
- 430 30. Masia M, Telenti G, Fernandez M, et al. SARS-CoV-2 Seroconversion and Viral Clearance in  
431 Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. *Open Forum*  
432 *Infect Dis.* 2021;8(2):ofab005.
- 433 31. Kutsuna S, Asai Y, Matsunaga A, et al. Factors associated with anti-SARS-CoV-2 IgG antibody  
434 production in patients convalescing from COVID-19. *J Infect Chemother.* 2021;27(6):808-813.
- 435 32. Shang Y, Liu T, Li J, Wang X, Zhou F. Factors affecting antibody response to SARS-CoV-2 in  
436 patients with severe COVID-19. *J Med Virol.* 2021;93(2):612-614.
- 437 33. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A  
438 systematic review. *PLoS One.* 2020;15(12):e0244126.
- 439 34. Cotugno N, Ruggiero A, Bonfante F, et al. Virological and immunological features of SARS-  
440 CoV-2-infected children who develop neutralizing antibodies. *Cell Rep.* 2021;34(11):108852.
- 441 35. Marchi S, Viviani S, Remarque EJ, et al. Characterization of antibody response in  
442 asymptomatic and symptomatic SARS-CoV-2 infection. *PLoS One.* 2021;16(7):e0253977.
- 443 36. Liu W, Russell RM, Bibollet-Ruche F, et al. Predictors of Nonseroconversion after SARS-CoV-2  
444 Infection. *Emerg Infect Dis.* 2021;27(9):2454-2458.
- 445 37. Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven  
446 serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation.  
447 *EClinicalMedicine.* 2020;29:100651.
- 448 38. Thiruvengadam R, Chattopadhyay S, Mehdi F, et al. Longitudinal Serology of SARS-CoV-2-  
449 Infected Individuals in India: A Prospective Cohort Study. *Am J Trop Med Hyg.* 2021.
- 450 39. Wellinghausen N, Plonne D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG  
451 response is different in COVID-19 outpatients and asymptomatic contact persons. *J Clin*  
452 *Viro.* 2020;130:104542.
- 453 40. Walker AS, Pritchard E, House T, et al. Ct threshold values, a proxy for viral load in  
454 community SARS-CoV-2 cases, demonstrate wide variation across populations and over  
455 time. *Elife.* 2021;10.
- 456 41. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic  
457 SARS-CoV-2 infections. *Nat Med.* 2020;26(8):1200-1204.
- 458 42. Bartsch YC, Wang C, Zohar T, et al. Humoral signatures of protective and pathological SARS-  
459 CoV-2 infection in children. *Nat Med.* 2021;27(3):454-462.

- 460 43. Dowell AC, Butler MS, Jinks E, et al. Children develop strong and sustained cross-reactive  
461 immune responses against Spike protein following SARS-CoV-2 infection, with enhanced  
462 recognition of variants of concern. *medRxiv*. 2021:2021.2004.2012.21255275.
- 463 44. Yates JL, Ehrbar DJ, Hunt DT, et al. Serological analysis reveals an imbalanced IgG subclass  
464 composition associated with COVID-19 disease severity. *Cell Rep Med*. 2021;2(7):100329.
- 465 45. Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the key to  
466 understanding SARS-CoV-2 susceptibility? *Lancet Child Adolesc Health*. 2020;4(6):414-416.
- 467 46. Yang F, Nielsen SCA, Hoh RA, et al. Shared B cell memory to coronaviruses and other  
468 pathogens varies in human age groups and tissues. *Science*. 2021;372(6543):738-741.
- 469 47. Bonfante F, Costenaro P, Cantarutti A, et al. Mild SARS-CoV-2 Infections and Neutralizing  
470 Antibody Titers. *Pediatrics*. 2021.
- 471 48. De Biasi S, Lo Tartaro D, Meschiari M, et al. Expansion of plasmablasts and loss of memory B  
472 cells in peripheral blood from COVID-19 patients with pneumonia. *Eur J Immunol*.  
473 2020;50(9):1283-1294.
- 474 49. Sosa-Hernandez VA, Torres-Ruiz J, Cervantes-Diaz R, et al. B Cell Subsets as Severity-  
475 Associated Signatures in COVID-19 Patients. *Front Immunol*. 2020;11:611004.
- 476 50. Cohen CA, Li APY, Hachim A, et al. SARS-CoV-2 specific T cell responses are lower in children  
477 and increase with age and time after infection. *Nat Commun*. 2021;12(1):4678.
- 478 51. Gong F, Dai Y, Zheng T, et al. Peripheral CD4+ T cell subsets and antibody response in COVID-  
479 19 convalescent individuals. *J Clin Invest*. 2020;130(12):6588-6599.
- 480 52. DiPiazza A, Richards KA, Knowlden ZA, Nayak JL, Sant AJ. The Role of CD4 T Cell Memory in  
481 Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza.  
482 *Front Immunol*. 2016;7:10.
- 483 53. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of  
484 parents with symptomatic COVID-19. *Nat Commun*. 2020;11(1):5703.
- 485 54. Loske J, Rohmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper  
486 airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol*. 2021.
- 487 55. Pierce CA, Sy S, Galen B, et al. Natural mucosal barriers and COVID-19 in children. *JCI Insight*.  
488 2021;6(9).
- 489 56. Letizia AG, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in  
490 healthy young adults: a prospective cohort study. *Lancet Respir Med*. 2021;9(7):712-720.
- 491 57. Tanne JH. Covid-19: Cases in children rise sharply in US as doctors call for vaccine approval.  
492 *BMJ*. 2021;374:n2030.
- 493 58. Baisheng Li AD, Kuibiao Li, Yao Hu, Zhencui Li, Qianling Xiong, Zhe Liu, Qianfang Guo, Lirong  
494 Zou, Huan Zhang, Meng Zhang, Fangzhu Ouyang, Juan Su, Wenzhe Su, Jing Xu, Huifang Lin,  
495 Jing Sun, Jingju Peng, Huiming Jiang, Pingping Zhou, Huanying Zhen, Jianpeng Xiao, Tao Liu,  
496 Rongfei Che, Hanri Zeng, Zhonghua Zheng, Yushi Huang, Jianxiang Yu, Lina Yi, Jie Wu,  
497 Jingdiao Chen, Haojie Zhong, Xiaoling Deng, Min Kang, Oliver G. Pybus, Matthew Hall,  
498 Katrina A. Lythgoe, Yan Li, Jun Yuan, Jianfeng He, Jing Lu. Viral infection and transmission in a  
499 large well-traced outbreak caused by the Delta SARS-CoV-2 variant. 2021. Accessed 11th  
500 August 2021.
- 501 59. Muecksch F, Wise H, Batchelor B, et al. Longitudinal Serological Analysis and Neutralizing  
502 Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis*.  
503 2021;223(3):389-398.
- 504 60. Rowntree LC, Chua BY, Nicholson S, et al. Robust correlations across six SARS-CoV-2 serology  
505 assays detecting distinct antibody features. *Clin Transl Immunology*. 2021;10(3):e1258.


506

507



508

509 Fig. 1: SARS-CoV-2 antibody response in children (blue) and adults (red) measured by three  
 510 serological assays; Diasorin (S1/S2), Wantai (RBD) and in-house ELISA (RBD/S1). (A) Mean  
 511 IgG SARS-CoV-2 antibody levels ( $\pm 95\%$  CI) at acute (median day 7-12, IQR: 4-13. Children,  
 512  $N=14$ ; Adult,  $N=17$ ) and convalescent (median day 41, IQR: 31-49. Children,  $N=57$ ; Adult,  
 513  $N=51$ ). (B) Venn diagram showing the concordance of seropositivity results between the three  
 514 serological assays ( $N=105-108$ ); two children and 1 adult sample were not tested by Wantai  
 515 assay. (C) Seropositivity rate in children and adults at convalescent period (median day 41.  
 516 Children,  $N=57$ ; Adult,  $N=51$ ). (D) SARS-CoV-2 IgG levels over time in children and adults  
 517 using an in-house ELISA; number of samples per timepoint: Children, Day 7 ( $N=13$ ), Day 41  
 518 ( $N=59$ ), Day 94 ( $N=26$ ); Adult, Day 12 ( $N=20$ ), Day 41 ( $N=57$ ), Day 94 ( $N=29$ ).




519

520 Fig. 2: Factors associated with SARS-CoV-2 antibody responses based on in-house ELISA  
 521 assay. (A) Seropositivity rate in children (blue) and adults (red) at convalescent period (median  
 522 day 41. Children, N=54; Adult, N=42) who were seropositive and seronegative by all three  
 523 serological assays. (B) Mean viral load (SD) between children (N=42) and adult (N=18) where  
 524 data were available. (C) Median days (IQR) between positive PCR diagnosis and convalescent  
 525 blood sampling between children (N=54) and adult (N=42). (D) Mean viral load (SD) between  
 526 children (N=42) and adult (N=18) stratified by serostatus. (E) Duration of viral clearance

527 (median days, IQR) stratified by serostatus (seronegative children, N=20, seropositive children,  
528 N=7; seronegative adult, N=4, seropositive adult, N=10). (F) Seropositivity rate stratified by  
529 sex. (G) Age of children and adults stratified by serostatus (Children, N=54; Adult, N=42)  
530 (Median, IQR). (H) Proportion of asymptomatic children and adults stratified by serostatus. (I)  
531 Median antibody levels (IQR) based on symptoms (left y-axis) and median fold-change in  
532 antibody levels between asymptomatic and symptomatic in children (N=6 vs N=14) and adults  
533 (N=2 vs N=30) (right y-axis). (J) Mean viral load (SD) stratified based on symptoms in children  
534 (asymptomatic, N=7 vs symptomatic, N=35) and adults (asymptomatic, N=2 vs symptomatic,  
535 N=17). (K) Correlation between antibody levels and viral load. (L) Correlation between  
536 antibody levels and age. Blue dots/bars represent children and red dots/bars represent adults.  
537 Seropositivity was defined as seropositive by all three assays. Pearson's correlation analysis  
538 was used to examine association. Ct value: cycle threshold.  
539





540

541 Fig. 3: *Ex vivo* cellular immune profile during convalescence period (median day 41) in  
542 children (PCR+sero-, N=14; PCR+sero+, N=13) and adults (PCR+sero-, N=4, PCR+sero+,  
543 N=15) following SARS-CoV-2 infection; PCR+sero-: dotted box, PCR+sero+: diagonal  
544 shaded box. An uninfected control group was included for comparison (PCR-sero-: children,  
545 N=11; adults, N=22); clear box. Bars represent median and range.